Vanda Pharmaceuticals Inc. (VNDA) Financial Statements
Vanda Pharmaceuticals Inc. (VNDA) reported trailing twelve-month revenue of $215.7M (up 6.0% year on year) and net income of -$274.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$143.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VNDAVanda Pharmaceuticals Inc.Follow VNDA — free
—
Price chart with a free account
- Market cap
- 242.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.3 | 32.7 | 33.9 | 50.2 | 109.9 | 146.0 | 165.1 | 193.1 | 227.2 | 248.2 | 268.7 | 254.4 | 192.6 | 198.8 | 216.1 | 215.7 | |
| Gross profit | — | 32.6 | — | 48.6 | 86.5 | 121.3 | 147.2 | 172.6 | 202.7 | 224.8 | 243.1 | 230.1 | 177.8 | 187.5 | 203.1 | 202.2 | |
| Research & development | 29.0 | 45.8 | 28.5 | 19.2 | 29.1 | 29.2 | 38.5 | 43.6 | 48.6 | 55.6 | 75.4 | 85.8 | 76.8 | 74.4 | 109.3 | 117.0 | |
| Operating income | -10.7 | -29.2 | -21.2 | 20.1 | -40.2 | -18.6 | -16.9 | 21.7 | 22.8 | 27.2 | 42.2 | 6.3 | -14.0 | -40.7 | -151.2 | -185.7 | |
| Pre-tax income | -10.2 | -27.7 | -21.1 | 20.2 | -39.9 | -17.9 | -15.4 | 25.3 | 29.0 | 31.7 | 42.4 | 11.3 | 6.3 | -22.9 | -138.6 | -177.2 | |
| Income tax | -0.4 | — | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | -86.5 | 8.3 | 9.2 | 5.0 | 3.8 | -4.0 | 81.8 | 97.7 | |
| Net income | -9.8 | -28.6 | -21.1 | 20.2 | -39.9 | -18.0 | -15.6 | 25.2 | 115.6 | 23.3 | 33.2 | 6.3 | 2.5 | -18.9 | -220.5 | -274.9 | |
| Diluted EPS ($) | -0.35 | -1.01 | -0.69 | 0.55 | -0.94 | -0.41 | -0.35 | 0.48 | 2.11 | 0.42 | 0.58 | 0.11 | 0.04 | -0.33 | -3.74 | -4.63 | |
| Diluted shares (mn) | 28.1 | 28.2 | 30.4 | 36.7 | 42.3 | 43.4 | 44.7 | 53.0 | 54.8 | 55.2 | 56.9 | 57.0 | 57.6 | 58.1 | 58.9 | — |
USD millions · SEC XBRL
Vanda Pharmaceuticals Inc. — questions
- What is Vanda Pharmaceuticals Inc.'s revenue?
- $215.7M over the twelve months to 2026-06-30, up 6.0% year on year, from its 10-Q and 10-K filings.
- What is Vanda Pharmaceuticals Inc.'s net income?
- -$274.9M over the twelve months to 2026-06-30.
- What is Vanda Pharmaceuticals Inc.'s free cash flow?
- -$143.0M over the twelve months to 2026-06-30.
- What are Vanda Pharmaceuticals Inc.'s diluted earnings per share?
- $-4.63 over the twelve months to 2026-06-30.
Every figure on this page comes from Vanda Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.